Australian clinical-stage biotechnology company Immutep (ASX:IMM) says it has received positive scientific advice from the European Medicines Agency for the continued development of its soluble LAG-3 protein and first-in-class MHC Class II agonist, eftilagimod alpha. …
Immutep receives positive scientific advice from the European Medicines Agency
August 2, 2023 Australian Biotech
Latest Video
New Stories
-
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech -
Government review and action timelines are in 'dog years' compared to AI
August 13, 2025 - - Latest News -
Australia is not alone in tripping over reform of medical device funding frameworks
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech